Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals Holding Corp. is a U.S.-based biopharmaceutical company that develops and commercializes therapies for central nervous system disorders, immunology, infectious diseases, and rare diseases. Its commercial portfolio includes TONMYA, Zembrace SymTouch, and Tosymra, while its development pipeline consists of investigational drug and biologic candidates.

−944,4 %

49,3 %

−946,2 %

+29,8 %

7.42

7.42

— Tonix Pharmaceuticals Holding Corp.
%
Commercial prescription products100% Approved branded medicines sold in the U.S., including TONMYA, Zembrace SymTouch, and Tosymra.
Clinical-stage pipeline0% Investigational drug and biologic candidates in CNS, immunology, infectious disease, and rare disease.

Tonix sells primarily to pharmaceutical wholesalers, pharmacies, and specialty distributors that place products into...

  • Pharmaceutical wholesalersprimary

    Buy TONMYA, Zembrace SymTouch, and Tosymra for downstream distribution into retail and specialty channels.

  • Pharmacies and specialty distributorsprimary

    Purchase branded products for dispensing to patients, especially where specialty handling or access support is needed.

  • Prescribing physiciansprimary

    Physicians in private practice and public treatment systems prescribe the products based on clinical need.

  • Payers and pharmacy benefit managerssecondary

    Review coverage, formulary placement, and reimbursement terms that affect patient access to TONMYA.

  • Patients with fibromyalgia or migrainesecondary

    End users of the medicines, supported through access and patient assistance programs.

Tonix is primarily a U.S. commercial-stage company, with its marketed products distributed in the United States through...

  • •United States is the core commercial market for all marketed products
  • •U.S. wholesalers and specialty pharmacies handle product distribution
  • •Commercial sales and marketing are run through Tonix Medicines, Inc.
  • •Market access work focuses on U.S. commercial plans and government programs
  • •Future pipeline programs may require foreign regulatory approvals

Tonix’s strategy centers on commercializing TONMYA for fibromyalgia through a targeted U.S...

01
Launch and expand TONMYA in fibromyalgiashort-term

TONMYA is the company’s key commercial growth driver and central to the current business model.

02
Protect and manage the existing migraine franchiseshort-term

Zembrace SymTouch and Tosymra provide an established commercial base and channel relationships.

03
Advance the development pipelinemedium-term

Pipeline programs diversify the company beyond current marketed products and support future value creation.

Tonix depends heavily on the commercial success of TONMYA, so weak uptake or reimbursement barriers could materially...

high

TONMYA may not achieve commercial success

The company states its prospects are dependent on successful commercialization of TONMYA.

Scope
Fibromyalgia launch
Materiality
high
high

Regulatory delays or adverse FDA actions

Drug development and commercialization depend on approvals, labeling, and compliance oversight.

Scope
Pipeline and marketed products
Materiality
high
high

Intellectual property disputes or weak protection

Loss of patent or trade secret protection can impair exclusivity and pricing power.

Scope
Commercial products and pipeline
Materiality
high
medium

Competition and technological change

Competing therapies can reduce prescribing share and make product candidates less attractive.

Scope
Fibromyalgia and migraine markets
Materiality
high
medium

Dependence on third-party manufacturers and distributors

Supply, logistics, and commercialization rely on contract vendors and external partners.

Scope
TONMYA and legacy products
Materiality
medium
medium

Foreign market and international regulatory risk

Future growth may depend partly on foreign markets, which add regulatory and execution complexity.

Scope
Pipeline expansion
Materiality
medium
Revenue deductions and variable consideration
Affects product revenue, gross margin, and quarter-to-quarter comparability
Government rebate timing
Can create future true-ups in revenue and receivables
Goodwill and intangible impairment
May cause non-cash charges that reduce earnings
Research and development expense recognition
Creates volatility tied to pipeline activity

Scilex Holding Co

SCLX · Biological Products, (No Diagnostic Substances)

AnTix Holdings, Inc.

IMTH · Services-Misc Health & Allied Services, NEC

SOLIGENIX, INC.

SNGX · Pharmaceutical Preparations

GoodRx Holdings, Inc.

GDRX · Services-Computer Processing & Data Preparation

Anixa Biosciences Inc

ANIX · Pharmaceutical Preparations

Janux Therapeutics, Inc.

JANX · Pharmaceutical Preparations

: 29.4.2026